NewAmsterdam Pharma (NAMS) Cash & Equivalents (2021 - 2026)

NewAmsterdam Pharma has disclosed Cash & Equivalents across 6 years of filings, most recently posting $457.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $457.6 million, down 38.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $457.6 million (down 38.86% YoY), and the FY2025 annual result was $490.0 million, down 36.51% from the prior year.
• Cash & Equivalents came in at $457.6 million for Q1 2026 at NewAmsterdam Pharma, down from $490.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $771.7 million in Q4 2024 to a low of $340.4 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $452.5 million (2022), against an average of $494.2 million.
• Across the five-year window, Cash & Equivalents soared 636.64% in 2022 and tumbled 38.86% in 2026, its largest moves.
• NewAmsterdam Pharma's Cash & Equivalents stood at $447.4 million in 2022, then decreased by 23.9% to $340.4 million in 2023, then surged by 126.68% to $771.7 million in 2024, then tumbled by 36.51% to $490.0 million in 2025, then fell by 6.61% to $457.6 million in 2026.
• The last three Cash & Equivalents figures came in at $457.6 million (Q1 2026), $490.0 million (Q4 2025), and $538.4 million (Q3 2025), per Business Quant data.